US Stock MarketDetailed Quotes

VYGR Voyager Therapeutics

Watchlist
  • 5.275
  • -0.110-2.04%
Trading Nov 19 15:34 ET
288.15MMarket Cap7.99P/E (TTM)
Intraday
  • 5D
  • Daily
  • Weekly
  • Monthly
  • 1Q
  • 1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Comments

    Tonyco
    Tonyco
    Nov 17 09:43
    $Voyager Therapeutics (VYGR.US)$
    Very oversold, less than 1% profitable positions, undervalued by all except p/e which is still under market avg.
    BeeDeeVee712
    BeeDeeVee712
    Oct 4 15:47
    $Voyager Therapeutics (VYGR.US)$ I got in on this around April of this year for around $6.30-6.40 and have been holding it just waiting for it to completely crash. I'm not sure exactly what caused the uptick today but I do know I'm extremely tempted to sell it all off and take the smaller profits (actually I'm definitely going to sell some for that), but I'm not sure, I think this company still has potential long-term, I was just blown away by how stagnant it had been for months. Anyone else have...
    3
    Tonyco
    Tonyco
    Sep 19 12:29
    $Voyager Therapeutics (VYGR.US)$
    This was over $10 recently, and earnings were great, except Wall St was scared of recession at the time. I'm guessing once they are satisfied, this will go back up
    Trytosaveabit
    Trytosaveabit
    Sep 5 07:04
    News
    $Voyager Therapeutics (VYGR.US)$ Press Release: Voyager Enters Into License for Next-Generation Capsid, Bringing Partnered Portfolio of TRACER-Enabled Gene Therapies to 14
    Dow Jones· 2 mins ago
    Voyager Enters into License for Next-Generation Capsid, Bringing Partnered Portfolio of TRACER-Enabled Gene Therapies to 14
    Voyager to receive upfront consideration of $15 million and is eligible to receive up to $305 million in potential associated milestone payments and royalties
    Jaguar8
    Jaguar8
    Sep 5 07:01
    NEWS
    $Voyager Therapeutics (VYGR.US)$
    Voyager Enters into License for Next-Generation Capsid, Bringing Partnered Portfolio of TRACER-Enabled Gene Therapies to 14
    Voyager Therapeutics (Nasdaq: VYGR) has announced a new license agreement with Novartis AG (NYSE: NVS) for a novel capsid from Voyager's TRACER™ capsid discovery platform. The capsid will be used in a gene therapy program targeting an undisclosed rare neurologic disease. This agreement expands Voyager's partnered portfolio of TRACER-enabl...
Read more

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
% Chg

No Data